Rating: Cautiously Bullish | Target Price: RMB 107–122 (base-case fair value range, 12 months) | Current Price: RMB 84.90 (close on 2026-10-09) | Margin of Safety: ~26% ((107−84.90)/84.90) | Time Horizon: 12 months
Company: MicroPort CardioFlow, a leading domestic player in aortic and peripheral vascular interventional devices, listed on the STAR Market. Market cap: RMB 10.465 billion (total shares outstanding: 123.26 million).
MicroPort CardioFlow is a high-quality device leader with a net margin of ~41%, operating ROE of ~27%, and RMB 2.18 billion of cash-like assets on the balance sheet (~21% of market cap). Yet the current price of RMB 84.90 has fallen to the very bottom of its 10-year valuation range (PE-TTM of 18.3x at roughly the 2nd percentile; PB of 2.46x at roughly the 0th percentile), a ~43% discount to the sell-side median target price of RMB 150. Three factors are weighing on the stock: the suspended aortic stent centralized procurement (the Hebei-led notice was issued 19 months ago with no bid opening yet), group-level liquidity concerns triggered by parent company MicroPort Scientific's trading halt, and growth downshifting as apparent profit growth slowed to +2.45% in 2026H1. Our judgment: the current price already embeds pessimistic pricing of "moderate price cuts + growth downshifting," while the high-margin overseas second growth curve and a dividend payout ratio near 50% provide downside protection; the base-case fair value is RMB 107–122 (+26% to +44% versus the current price). However, the tail scenario for aortic procurement (ex-factory price cuts above 40% with insufficient volume growth) implies a bear-case range of RMB 54–65—the risk is real. We are cautiously bullish, with two key verification milestones: the final procurement rules and the parent company's resumption of trading.
Opportunity definition: Over the next 12–18 months, there is an opportunity for convergence of the market's dual discount for "aortic procurement tail risk + MicroPort group crisis"—evidence grade B (first-hand financial statements and official procurement documents are solid, but the distribution of procurement outcomes is wide and the sell-side sample is thin); the environment is a policy headwind period (price governance as the norm).
Changes underway (three parallel tracks):
Primary share price driver: Timing and price-cut rules for aortic procurement (pricing power of a business accounting for ~73–76% of revenue) ＞ parent company resumption ＞ delivery of overseas and peripheral growth. Verifiable expectation gap: Back-solving from the current price implies normalized net profit attributable to shareholders of ~RMB 439 million (~23% below TTM's RMB 571 million, using the company's 3-year median PE of 23.8x; this back-solve is sensitive to the multiple chosen—using 15–25x, the implied discount swings between -3% and -42%; the directional conclusion is that the current price is priced significantly below the sell-side consensus trajectory, not a precise figure). Verification catalysts and falsification conditions: The Q3 report on 2026-10-30 (nominal overseas growth, whether peripheral turns positive, trends in receivables and rebates); procurement documents (price-cap rules, innovation exception clauses); MicroPort's resumption announcement.
Key evidence:
The causes of the low percentile are multiple and must be honestly deconstructed: growth downshifting (2026H1 attributable profit only +2.45%), parent company suspension discount, and procurement suspension stacked together; moreover, ROE has declined from 22.2% in 2022 to 14.3% in 2025, so part of the low PB is a reasonable re-pricing of a lower profit center, not entirely mispricing. But two points support the judgment of "excessive pessimism": first, after the 2024 price-cut shock, the company's ex-non-recurring profit fell -14.4% that year and rebounded to +27.0% the following year (recovery occurred in the second year after the price cut, and management itself acknowledged the industry did not rapidly ramp volume after the cut—the offset came from overseas and new-product mix rather than volume elasticity), showing profit resilience stems from product iteration rather than luck; second, the current price implies a perpetual growth rate of only ~4.3% (FCFE back-solve, r=9.5%), below the 2022–2025 revenue CAGR of 14.6% and consensus net profit CAGR of 11.8%. Re-rating triggers are clarity on procurement rules (even a moderate outcome compresses the uncertainty discount simply by removing the overhang) or the parent company's resumption. The thesis fails if the Q3 report confirms ex-non-recurring growth turning negative and overseas growth falling below 10%, or if procurement is implemented at 40%+ price cuts with no exception clauses.
Key evidence:
Overseas is a genuinely "procurement-immune" leg: unconstrained by domestic medical insurance pricing, gross margin of 62% and improving, Europe above industry growth, Latin America leading, Asia-Pacific (Vietnam/Thailand/India) accelerating. But the composition of the "procurement-immune portfolio" must be clarified—peripheral has already been substantially covered by two rounds of procurement (peripheral vascular stent inter-provincial alliance executed from August 2025, drug-coated balloon national procurement executed May 2026). In 2026H1, peripheral revenue was RMB 194 million, about -3% YoY, with accrued sales rebates up +382% from the beginning of the period (RMB 54.877 million); the evidence of discounting-for-volume is clear, so peripheral is currently in the procurement impact zone, not an immune zone. Quantitatively, overseas + peripheral accounted for 42.4% of revenue in 2026H1; assuming full-year overseas of RMB 300–320 million and peripheral H2 ≥ RMB 220 million, the full-year 2026 share would be ~48–50%; "over half" must wait until 2027 and depends on peripheral's H2 sequential volume ramp. On the pipeline, 4 products including Fishhawk (mechanical thrombectomy catheter) were approved in 2026H1, and Aegis II/HepaFlow/SunRiver are under registration review; the cycle from approval to large-scale commercialization is long (management's own words), so volume contributions should be modeled conservatively. If nominal overseas growth (non-ex-FX) falls below 15% for two consecutive quarters, or peripheral fails to turn positive in 2026H2, this thesis must be downgraded.
Key evidence:
The aortic business generated revenue of RMB 600 million in 2026H1, 75.6% of total revenue, with a gross margin of 79.0%, contributing ~80% of company gross profit (estimate: aortic gross profit RMB 781 million / total main-business gross profit RMB 960 million ≈ 81.3%, 2025 basis). Scenario analysis must distinguish magnitudes: under a static calculation of 40% ex-factory price cut with 10–20% volume growth, 2027E attributable net profit falls roughly -28% to -45% (RMB 380–480 million); the extreme range of below -55% requires stacked volume collapse (volume below -26%) or share loss from failed bids—lower probability than the former but not excludable—the similarly-sized peripheral stent category has already executed alliance procurement, proving that an aortic bid opening is only a matter of time. Precedents: on the day of the NHSA inquiry in August 2024 the stock fell sharply, and on 2025-02-25, the day of Hebei's official announcement, the stock fell -9.45%; share prices retreat ahead during expectation-building phases. Meanwhile, the peripheral stent alliance compressed single-product prices from tens of thousands of yuan to the RMB 3,000–4,000 level, and coronary drug balloons broadly to the RMB 2,000 level, showing that procurement price cuts in vascular intervention have never been moderate. Innovation groupings and exception clauses in procurement rules (the fifth national procurement round allowed appropriate price premiums for next-generation products) are key to whether CardioFlow's branched/multibranched innovative products receive premium protection. If procurement documents include a national-scale batch, or if price cuts ≥40% come with no exception clauses, the investment thesis requires a full re-assessment.
Key evidence:
The dual nature of the quality profile must be presented in full: on the positive side—net margin of ~41% is the highest among peers (Huatai 31.3%, Lifetech ~26%); as of end-June 2026, cash of RMB 1.275 billion plus structured deposits of RMB 907 million totaled RMB 2.182 billion, with interest-bearing debt of only ~RMB 18 million; cumulative buybacks of RMB 240 million in 2024–2025 (buyback account: 2.421 million shares); 2025 dividends + buybacks totaled 70.67% of attributable net profit. Corrections to the headline figures: of the RMB 2.18 billion of cash-like assets, ~RMB 870 million is committed fundraising-project investment (global headquarters base, etc.); freely deployable portion is ~RMB 1.3 billion, ~12% of market cap; dividend yield ~2.66%; the thickness of the "cash-like + dividend floor" is about half the book-basis figure, and absolute dividends presuppose profits don't collapse. Deteriorating signals: receivables +75.5% in 2025 and another +23.5% in 2026H1 (~twice revenue growth), accrued rebates +382% in half a year—pointing to increased channel discounting and lengthening payment terms; channel destocking would crystallize as impairments. R&D spending bottomed in 2025 (RMB 126 million, -25.5%) and rebounded +26% in 2026H1 (expensed portion +42.4%, eroding near-term profit in the opposite direction); the risk direction has flipped from "R&D contraction hurting the pipeline" to "expense rebound pressuring profit"—whether R&D as a share of revenue returns to the 12–15% range is a key validation point for the 2026 annual report.
Key evidence:
CardioFlow's 39.77% stake is controlled by MicroPort Scientific via Hong Kong CardioFlow / Virgin Islands CardioFlow. The earn-out gap (actual USD 38.43 million vs. required USD 90 million) suggests upward—not downward—pressure on the group to dispose of assets; the stake at the Hong Kong CardioFlow level is one of the group's highest-quality potential disposal targets. Probability is hard to quantify, but if it occurs, the event-window shock would be roughly -15% to -25%, and could be deeper if the suspension is prolonged (qualified audit opinion, chained convertible bond redemption failure). Conversely, a resumption (especially with an unqualified interim audit opinion) would remove the subsidiary valuation discount; estimated recovery elasticity of 5–15%. CardioFlow itself has strong operational independence: RMB 2.18 billion cash-like assets, interim dividend paid as usual, no pledges or unlocks; group risk is currently a valuation discount and sentiment variable, with no evidence of cash flow transmission yet. Related-party transactions are manageable (purchases from + services to the MicroPort system total ~RMB 58 million, within ~4% of revenue), but related-party receivable exposure in the interim report requires ongoing tracking.
| Metric | 2023FY | 2024FY | 2025FY | 2026H1 (latest period) |
|---|---|---|---|---|
| Revenue (RMB 100M) | 11.87 | 12.06 | 13.51 | 7.94 |
| Revenue YoY | +32.4% | +1.6% | +12.0% | +11.1% |
| Net profit attributable to shareholders (RMB 100M) | 4.92 | 5.02 | 5.63 | 3.22 |
| Attributable net profit YoY | +38.0% | +2.0% | +12.2% | +2.5% |
| Ex-non-recurring attributable net profit (RMB 100M) | 4.62 | 3.95 | 5.02 | 2.99 |
| Ex-non-recurring YoY | +27.0% (as listed in table) | -14.4% | +27.0% | +10.5% |
| Gross margin (main business) | 76.45% | 72.98% | 71.09% | 71.36% |
| Net margin | 41.5% | 41.6% | 41.7% | 40.6% |
| Operating cash flow (RMB 100M) | 5.58 | 3.74 | 5.73 | 2.90 |
| Free cash flow (RMB 100M, OCF−CapEx) | 3.68 | 1.61 | 2.70 | 2.10 |
| Cash-like assets (cash + trading financial assets, RMB 100M) | — | — | — | 21.82 (2026-06-30) |
| Interest-bearing debt (RMB 100M) | — | — | 0.29 (2025-12-31) | 0.18 (2026-06-30) |
| Debt-to-asset ratio | 9.0% | 10.9% | 11.7% | 13.7% |
Note: The company does not disclose a custom-defined free cash flow; this table uses OCF − cash outlays for long-term asset purchases. Cash-like assets at end-2023/2024 were not verified in this data pull and are not shown. The company is in a net-cash position; net debt/EBITDA is not applicable.
Reasons for metric changes (YoY ≥ ±20% excerpts, all per company disclosure):
In 2026H1, revenue was RMB 794 million (+11.13%), net profit attributable to parent RMB 322 million (+2.45%), and non-GAAP (recurring) profit RMB 299 million (+10.45%). Q2 standalone net profit attributable was RMB 168 million (roughly -9% YoY), the main driver of the apparent growth slowdown. The three business lines diverged clearly: aortic stents generated RMB 600 million (+17%, volume-driven); peripheral and others RMB 194 million (about -3%, with the drug-balloon national VBP implemented in May 2026 pressuring prices); overseas RMB 143 million (management-reported FX-adjusted +21%+, accounting for 18% of revenue). On the profit side, R&D expenses +42.4% (clinical restart of new projects, lower capitalization rate) and lower government subsidies (other income -50.1%) together dragged apparent profit by roughly 3–4 percentage points; the non-GAAP growth rate (+10.5%) better represents the operating trend. Gross margin stabilized sequentially at 71.36% (vs. 71.09% for full-year 2025). Versus expectations: the company provides no quantitative guidance; H1 attributable profit achieved about 52.8% of the sell-side consensus full-year estimate of RMB 610 million—on a "in line but no surprise" trajectory. The stock weakened after the interim results, with forward PE dipping to around 16.5x at one point, reflecting the market's dual concerns over the Q2 decline and VBP uncertainty rather than systematic earnings downgrades (consensus downgraded only ~3% over the past 90 days). Key watch points at the Q3 report due 2026-10-30: overseas nominal growth, whether the peripheral business turns positive, and trends in receivables and accrued rebates.
Business model: R&D and manufacturing of high-value consumables (Class III implants) plus buy-and-sell distribution. Asset-light on the books—fixed assets of only RMB 94 million, about 2% of total assets; value is embedded in registrations, clinical data, and physician education systems (off-balance-sheet intangibles); revenue is entirely from one-time consumable sales with no recurring revenue; pricing power is structurally weakening under medical insurance price governance (implied ex-factory average price of aortic products: 19,313→17,081→16,003 RMB/kit, a cumulative ~-17% over two years; the company has not separately quantified this). Overseas operations run through the OMD/Lombard acquisitions.
Cash content of earnings: OCF/net profit was 1.13→0.74→1.02 for 2023–2025 (0.90 in 2026H1), broadly on target; but FCF/net profit was 0.75→0.32→0.48, below 0.5 for two consecutive years—nearly half of profits swallowed by capex, mainly due to the RMB 1.9 billion global headquarters (growth investment; construction extended to Sep 2027), not runaway maintenance spending. Recurring earnings test: 2024 attributable profit of RMB 502 million included a RMB 56.46 million OMD remeasurement gain, with non-GAAP at RMB 395 million (a -21% gap); in 2025 non-recurring items of RMB 61.05 million (mostly government subsidies) accounted for 10.8% of attributable profit—core earnings quality remains acceptable.
Return on capital: Estimated ROIC of ~12.6%→14.5%→13.5% for 2023–2025, persistently above the estimated WACC of 9.5%—excess returns are positive but below the 15% strong-moat threshold—price governance eroding pricing power being the main cause. ROE fell from 22.2% in 2022 to 14.3% in 2025; excluding RMB 2.18 billion of cash-like assets, operating ROE is about 27%.
Capex quality: 2025 CapEx was RMB 303 million (+42.5%), CapEx/D&A about 3.4x; the company does not split maintenance vs. growth investment, but the fixed asset base suggests maintenance spending is near depreciation levels (~RMB 100 million/year), with the bulk being campus expansion—judged as growth-oriented rather than a capital black hole, at the cost of suppressed free cash flow in 2026–2027 and added annual depreciation of roughly RMB 30–50 million once the campus comes online.
Quality red flags (with numbers): ① Surging receivables + top-5 receivables at 72.38% (68.12% in 2024); ② top-5 customers at 68.24% of sales, largest at 28.69%—under the buy-and-sell distribution model, channel bargaining power is rising; ③ goodwill of RMB 465 million (11.4% of net assets), with ~10% margin of safety in impairment testing (recoverable RMB 703 million vs. carrying value RMB 637 million).
Credibility: partially delivered, pragmatic but imprecise in wording. The 2024 registration commitments (occlusion balloon, venous stent, etc.) were all delivered (Class III registrations up from 13 to 20); the 2025 commitment of "at least six approvals" saw only 4 actually approved (Fishhawk/TorqueFlex deferred to H1 2026—delayed but delivered); the blemish is that the 2025 annual report described FinderSphere/HawkMaster as both "approved during the reporting period" and "to be approved in 2026," a contradiction. No quantitative revenue/profit guidance is ever given; when asked about growth conditions, management only responds that "there are clear internal operating targets and assessment mechanisms"—hard for investors to anchor on.
Shareholder friendliness: friendly. Cash payout ratios for four consecutive periods at 48.7%–50.4% (FY2023: RMB 248 million/50.40%; 1H2024: RMB 203 million/50.40%; FY2025: RMB 278 million/49.35%; 1H2026: RMB 157 million/48.73%); buybacks across two programs in 2024–2025 totaled 2,421,043 shares for RMB 240 million; in 2025 dividends + buybacks equaled 70.67% of attributable profit. Offset: the December 2023 private placement raised RMB 1.809 billion with ~13% dilution (issue price RMB 168.33; the price has since halved, leaving placement participants deeply underwater).
Risk signals: Governance turmoil—chairman changed twice during 2023–2025 (the current chairman comes from a MicroPort-affiliated CFO background), board secretary replaced in Sep 2025, supervisory board abolished in Aug 2025; related-party transactions at ~2–4% of revenue, manageable; in 2024 the company paid back taxes of RMB 62.23 million plus RMB 6.9 million in late-payment penalties, exposing a one-off tax compliance flaw.
| Segment | 2025 Revenue | Share | Gross Margin | YoY | Business Logic in One Line |
|---|---|---|---|---|---|
| Aortic stents | RMB 988 million | 73.2% | 79.01% (+4.49pp) | +9.26% (volume +16.61%, implied price ~-6.3%) | Absolute domestic leader; Castor/Cratos innovation premium + cost reduction offsetting VBP price cuts |
| Peripheral and others (incl. intraoperative stents) | RMB 362 million | 26.8% | 49.48% (-18.82pp) | +21.50% (volume +130.88%, sharp price decline) | VBP epicenter + low-margin agency products + overseas consolidation; trading price for volume |
| Of which: Overseas (by geography) | RMB 257 million | 19.0% | 62.34% (+13.11pp) | +56.53% | Second curve unconstrained by domestic VBP |
Profit engine: Estimated by "revenue share × gross margin," aortic products contribute ~81.3% of gross profit (RMB 781 million / RMB 960 million)—with 73% of revenue, aortic products generate over 80% of gross profit; earnings remain essentially a single aortic engine, which is the financial root of the high VBP risk weighting. Gross margin structural gap of 29.5pp (79.0% vs. 49.5%): aortic products are innovative branched stents with the highest regulatory and academic barriers; the peripheral segment faces VBP price cuts + volume ramp in low-margin agency products (shockwave balloon and other agency revenue +314.59%) + dilution from overseas consolidation—three factors combined, and the company has not provided a separate breakdown (see the "Accounting Practices and Cross-Period Consistency" chapter for disclosure flaws). In 2026H1, aortic was 75.6%, peripheral 24.4%, overseas 18%—domestic aortic exposure (total revenue minus overseas minus peripheral) is about 57.6%.
Accounting red flags (pattern + severity + evidence):
Cross-period consistency: R&D intensity (R&D/revenue) fell 21.94%→14.05%→9.35% (contradicting the stated strategy of "continuously increasing R&D investment"; the company attributes this to "multiple peripheral projects completing clinical trials, a temporary pullback in spending"—consistent with facts but unfavorable in direction); implied aortic average price fell two years straight, -17% (only qualitative disclosure by the company, no quantification); peripheral gross margin stepped down -23pp over three years (no breakdown given); the 2024 OCF plunge of 33% has no line-item explanation (unexplained by the company). Overall judgment: no sign of systematic fraud, but three areas are loose—channel concessions, R&D capitalization, and disclosure granularity; earnings quality is deteriorating at the margin, requiring quarterly tracking of receivables, rebates, and impairments (single-quarter credit impairment >RMB 15 million or DSO breaching 130 days as warning thresholds).
Current market data (all based on the frozen closing anchor of 2026-10-09): share price RMB 84.90, market cap RMB 10.465 billion, total shares 123.26 million. PE(TTM) 18.33x (~3%/5%/3%/2% percentile over 1/3/5/10 years), non-GAAP PE(TTM) 19.72x, forward PE 16.8x (2026E)/14.6x (2027E), PEG ~1.42, PB 2.46x (~0% percentile over 10 years), PS(TTM) 7.32x, dividend yield ~2.66%. Earnings representativeness test: the Castor price-cut shock was absorbed in 2024–2025, gross margin stabilized at 71.1–71.4%, non-GAAP TTM +10.5%—current earnings are broadly representative, so PE percentile can serve as a cheap/expensive signal; but note ROE fell from 22.2% to 14.3%, so the low PB percentile partly reflects justified repricing; percentiles are only one reference.
Peer comparison (2026-10-09):
| Company | PE(TTM) | PB | 2025 Revenue Growth | Net Margin | Notes |
|---|---|---|---|---|---|
| HeartFlow/Endovascular (Xinmai Medical) | 18.33 | 2.46 | +12.0% | 41.7% | Domestic aortic leader; highest net margin among peers |
| Huitai Medical (688617) | 36.85 | 11.13 | +25.1% | 31.3% | EP + coronary + peripheral platform, Mindray-controlled, ROE 29.3% |
| Micro-Tech (Nanjing) (688029) | 30.66 | 3.74 | N/A | N/A | Endoscopy comparable; PE at its own historical high |
| Lifetech Scientific (1302.HK) | 93.0 (distorted basis, to be verified) | 1.64 | +5.1% | ~26% | HK liquidity discount; distorted earnings base |
What expectations the market has already priced in: Backing out from the company's 3-year median PE of 23.8x, the current price implies a "normalized" attributable profit of ~RMB 439 million, about 23% below the TTM RMB 571 million; backing out from FCFE implies a perpetual growth rate of ~4.3%/year. This back-calculation is sensitive to the multiple chosen (15–25x corresponds to a -3% to -42% discount), so precise values are unreliable, but the directional conclusion is robust: the current price requires the market to believe in "further aortic price cuts across the board and near-zero long-term growth," whereas reality shows revenue still compounding at 11%, single-product price-cut shocks offset within a year, and sell-side consensus at an 11.8% net profit CAGR for 2026–27. The sell-side sample is thin (earnings forecasts n=6, target prices n=2, zero sell ratings)—thick right tail, empty left tail, so consensus cannot be treated as a neutral anchor—but the current price trades at a 43.4% discount to the median target of RMB 150; even applying a 30% haircut across all sell-side forecasts, substantial upside remains.
Three-tier value (EPV): Asset value (book value per share) RMB 34.54—device registrations/physician education systems are not on the books, so the true liquidation floor is above book; zero-growth EPV RMB 60.51/share (bridged from TTM non-GAAP RMB 531 million: + D&A RMB 120 million − after-tax interest RMB 38 million − maintenance capex RMB 110 million ≈ FCFF RMB 503 million = RMB 4.08/share, ÷ WACC 9.5% + net cash RMB 17.56/share, whole-enterprise basis); of the current price of RMB 84.90, EPV accounts for ~71.3% and the growth option ~28.7% (per this report's EPV framework). Implication: even paying nothing for growth, RMB 60.5 forms a valuation floor reference; the current ~40% premium to EPV requires second-curve delivery to support—precisely what the C2 thesis must validate. The option share is not low, so the claim that "the market pays only for zero growth" does not hold here.
Three scenarios and odds (12 months; fair ranges based on 2027E earnings and exit multiples):
| Scenario | Probability | Fair Range | vs. Current | Swing Factors |
|---|---|---|---|---|
| Bear | 25% | RMB 54–65 | -24% to -36% | Provincial-alliance/national VBP lands in 2027 with 40%+ ex-factory price cuts and <20% volume growth: 2027–28E attributable profit falls to ~RMB 390–420 million (-35% to -40% vs. no-VBP baseline), exit at 17–19x (anchor: above the company's own 3-year PE trough of 16x, within the range for VBP-normalized medtech) |
| Base | 50% | RMB 107–122 | +26% to +44% | Mild regional VBP (20–30% cuts, price-for-volume) + 20–25% overseas growth and peripheral volume offsetting: 2027E attributable profit RMB 660–700 million × exit 20–21.5x (anchor: 0.85x on the 3-year median PE of 23.8x, ≈55–65% of Huitai's 36.9x, independent of the current multiple) |
| Bull | 25% | RMB 152–170 | +79% to +100% | VBP slower than expected/provincial pilots only + rising Hector overseas expectations + 25%+ overseas growth: 2027E attributable profit RMB 720–750 million × 26–28x (anchor: 0.85x on the company's own 5-year PE center of 31x, close to CICC's RMB 150 framework) |
Probability-weighted expectation ~RMB 112.4 (+32.4%). The odds distribution skews positive but the downside tail is real: to bear-case midpoint -29.9%, low end -36.4%; to base-case midpoint +34.9%, bull-case midpoint +89.6%. External anchor comparison: the most pessimistic sell-side target is RMB 94 (third-party aggregate lower bound, 5 analysts, zero sell ratings—distribution excludes policy tail scenarios, so not comparable to the bear case constructed here on independent stress assumptions and thus not adopted as the bear boundary); the most optimistic is CICC's RMB 150 (2026/27E PE 30/26x, whose multiple assumptions imply overall manageable VBP impact; our base case is ~25% more conservative).
House earnings forecasts (results reconciliation anchor):
| Period | Revenue | Attributable Net Profit | Key Assumptions |
|---|---|---|---|
| 2026E (this report) | RMB 1,495–1,515 million (+10.6% to +12.2%) | RMB 591–609 million (+4.9% to +8.1%) | Aortic volume +8–10% with stable prices, peripheral turning positive in H2, overseas +20%+ to RMB 290–300 million, recovering R&D expenses constraining profit elasticity |
| 2026E (sell-side consensus, n=6) | — | ~RMB 610 million (+8.5%) | This report 0–3% lower; difference lies in more conservative R&D and H2 price-risk assumptions |
| 2027E (this report) | RMB 1,660–1,740 million | RMB 660–700 million (mild VBP); RMB 600–650 million (if heavy VBP) | New depreciation of RMB 30–50 million from campus startup; R&D ratio 10–11% |
| 2027E (sell-side consensus) | — | ~RMB 705 million (+15.6%) | Most not fully factoring in regional VBP price cuts |
Management guidance: no quantitative guidance (only qualitative—"peripheral likely to trade price for volume; overseas as the second curve"); forecast reconciliation uses this report and the sell-side numbers.
Conclusion: Undervalued, target price range RMB 107–122 (= base-case fair value), margin of safety ~26%. Evaluate quality and price separately: quality is strong (net margin/gross margin/cash/dividends all top-tier among peers; ROIC above cost of capital though pricing power is weakening); price is cheap (extremely low percentiles + implied expectations notably more pessimistic than the consensus trajectory). The cost of cheapness is having to bear the policy tail of aortic VBP—this is a "quality company + pessimistic pricing" combination, not mispricing. The anchoring basis for the base-case exit multiple of 20–21.5x: 0.85x on the company's 3-year median PE of 23.8x (a re-rating as the growth center declines from 40%+ to 10–15%) + a 55–65% discount to peers Huitai at 36.9x and Micro-Tech at 30.7x, both independent of the company's current multiple; we do not believe historical median multiples can fully revert while VBP hangs overhead, hence below the sell-side implied 26–30x.
1. Industry Size. The company operates in China's aortic and peripheral vascular interventional device market (both Class III high-value consumables, excluding coronary/neuro-intervention/electrophysiology). Core figures (Frost & Sullivan, ex-factory prices, as cited in HeartFlow Medical's 2024 annual report—industry association/institution-level primary sources): China's aortic endovascular stent market was RMB 2.40 billion in 2021 → RMB 3.94 billion in 2024 (three-year CAGR of ~18%, a volume-and-price-rising phase) → RMB 2.91 billion in 2025E (a contraction year per Sullivan's assumptions on VBP/DRG implementation) → RMB 4.31 billion in 2030E (2021–2030 CAGR of ~6.7%, of which 2024–2030 is ~1.5%—volume up, price down). Thoracic : abdominal aorta share ratio of approximately 53.2% : 46.8%. Peripheral intervention shows a steeper growth curve: peripheral arterial stents + balloons grew from RMB 2.17 billion in 2021 → RMB 6.80 billion in 2030E (CAGR ~13.5%); peripheral venous intervention devices from RMB 1.01 billion in 2021 → RMB 4.99 billion in 2030E (CAGR ~19.4%); intraoperative stents were only RMB 66 million in 2021 (niche). Global aortic endovascular stent market: USD 1.78 billion in 2021 → USD 3.23 billion in 2030E (CAGR ~6.8%; 2024 global size aggregator reference of USD 3.35–3.6 billion, low source reliability, pending verification). Structural conclusion: China's aortic segment is a "volume growth, price maturation" market—procedure volumes on the demand side grow long-term, but from 2025 ex-factory market size contracts ~26% due to price governance, leaving mid-to-low single-digit CAGR for industry size over the next five years; limited room for "compensating price with volume" in the single market. Peripheral and overseas markets are the true high-growth pools.
2. Value Chain and Value Distribution. Upstream (polyester/PET graft fabrics, ePTFE, nitinol, precision parts for delivery systems) suppliers are fragmented with multi-sourcing possible; device makers have strong bargaining power over upstream—value does not lie in raw materials (HeartFlow's aortic gross margin is 79%). Midstream manufacturers (foreign players Medtronic/Gore/Cook + domestic HeartFlow/Lifetech/Huimai Taike, etc.) handle R&D, registration, and production, where gross profit mainly accrues. Downstream: buyout-model distributors → vascular surgery/interventional departments of Grade IIIA hospitals → medical insurance reimbursement. Channels were once the largest variable in profit distribution: Castor's ex-factory price was ~RMB 50,000, but the terminal price through agents exceeded RMB 120,000 (markup over 140%); after public inquiry by the National Healthcare Security Administration (NHSA) in Aug 2024, the terminal price dropped to ~RMB 70,000—price governance essentially redistributes channel excess profits to upstream manufacturers and the insurance payer; HeartFlow's ex-factory damage was smaller than the terminal price decline. The company sits at the core midstream position: strong bargaining power over upstream, but its bargaining power over downstream (medical insurance as monopsony payer) is systematically weakened.
3. Supply-Demand and Competitive Landscape. Demand: a large aortic disease population in China but low screening/treatment rates; endovascular intervention penetration was ~1.6% in 2018 vs 3.1% in the US (Guangzheng Hengsheng), with ~49,000 procedures in 2024 (industry citation, pending verification); aging and chronic diseases (PAD/diabetes) drive peripheral demand. Supply: the aortic segment is an oligopoly—first tier: Medtronic, HeartFlow Medical; second tier: Gore, Lifetech, Cordis, Cook; the top players hold over 60% combined (LeadLeo Research 2024; precise CR3/CR5 not disclosed/not obtained). Peripheral is foreign-dominated (Medtronic/Boston Scientific/Abbott) with low domestic substitution (<20%). Entry barriers: 5–10 year Class III registration cycle + clinical data and physician learning curves (Castor's first-mover academic evidence barrier) + stent-graft braiding know-how + Grade IIIA hospital channels. Price war has become the main battlefield: all 11 thoracic aortic stent players nationwide cut prices below RMB 80,000; the lowest bids in peripheral stent national VBP all came from imported brands. Substitution threat: open surgery is irreplaceable in complex cases but keeps being displaced by endovascular approaches; branched/multi-branched fully endovascular stents replace hybrid procedures, benefiting top innovators.
4. Cycles and Regulation. The industry faces the overlap of "mid-stage demand growth + early-stage price decline." Regulation is the primary variable: ① Aortic stent grafts have not yet been included in national VBP (no aortic national batch as of Oct 2026), but the NHSA's public inquiry into Castor in Aug 2024 opened price governance, and a product information notice issued by the Hebei-led aortic VBP in Feb 2025 remains suspended to date; ② The fifth national VBP batch (bids opened Dec 2024): peripheral vascular stents, 258,000-unit demand, 18 winners, implemented May 2025, with unit prices falling from tens of thousands of RMB to the RMB 3,000–4,000 level; ③ The sixth national VBP batch (bids opened Jan 2026): drug-coated balloons with nationwide execution in May 2026 (coronary DCBs broadly cut to the RMB 2,000 level; peripheral cuts shallower than coronary); ④ Provincial alliances keep expanding (Henan 19-province alliance average cut of 53.6%, Hebei 4-category peripheral alliance, etc.); ⑤ Nationwide DRG/DIP rollout compresses terminal use-cost sensitivity; ⑥ Hedge mechanisms: the fifth batch rules allow moderate price premiums for next-generation products, and the innovation green channel was previously excluded from VBP—"innovation-group pricing premium" is a policy-driven way out for top manufacturers. Direction: headwinds dominate (systematic compression of per-product lifecycle value), but procedure volume release, innovation premiums, and overseas markets (unconstrained by domestic medical insurance) provide offsets.
5. Peer Benchmarking (basis: 2025 annual reports/earnings announcements):
| Company | 2025 Revenue | Growth | Gross Margin | Net Margin/Profit | Key Differences vs HeartFlow |
|---|---|---|---|---|---|
| HeartFlow Medical | RMB 1.351 bn | +12.0% | 71.1% | Net to parent RMB 563 mn / 41.7% | Absolute domestic leader in aortic intervention; highest single-product depth and net margin, but lags in growth elasticity |
| ShapeMemory (Huitai Medical) | RMB 2.584 bn | +25.1% | 72.9% | Net to parent RMB 821 mn / 31.3% | Multi-segment platform in electrophysiology + coronary + peripheral, backed by Mindray; larger scale and faster growth |
| Lifetech Scientific | RMB 1.370 bn | +5.1% | 74.4% | Adjusted net ~RMB 353 mn / ~26% | Venous filters/occluders plus multi-point aortic layout; overseas share of ~26% above HeartFlow |
| Fountain Medical (Guichuang Tongqiao) | RMB 1.057 bn | +35.1% | 72.1% | Net profit RMB 244 mn | Neuro-intervention leader + peripheral as second curve; overseas +115.5%, highest elasticity |
6. Company Industry Position: HeartFlow is the niche leader in China's aortic and peripheral intervention space—tied for first tier with Medtronic in aortic intervention (LeadLeo 2024); absolutely dominant domestically in branched thoracic aortic stents (Castor is the world's first branched aortic stent, covering over 1,450 terminal hospitals, contributing 38–41% of revenue as a single product in 2023). Market share basis note: the company's 2025 earnings flash report claims steady market share gains (company basis); LeadLeo's 2024 ranking places it in the first tier (third-party basis)—the two bases align in direction (first tier, non-precise share); precise market share not obtained. The cost of share gains is price: ASP down 17% over two years—"trading price for share" rather than pricing-power-driven growth. Moat sources: registration certificate matrix (20+ Class III certificates, 120+ overseas registrations) + physician learning-curve stickiness + MicroPort's academic channels; overseas share (<2% of the ~USD 4 bn global aortic pie) provides long-term catch-up runway.
Two defining dimensions distinguish vascular intervention high-value consumables from general manufacturing; they are easily missed by generic financial frameworks and are therefore listed separately.
(1) Pricing-power implications of VBP rules. The market's current valuation of HeartFlow essentially prices not growth, but "the pace of earnings decay of its domestic aortic exposure (~58%) under VBP." Three reference points: ① The peripheral vascular stent inter-provincial alliance, also led by Hebei, has already been executed (tens of thousands of RMB → RMB 3,000–4,000 level, cuts of 80%+)—if aortic cuts follow this magnitude, this falls into worse-than-bear-case territory in this report; ② Coronary DCBs broadly cut to the RMB 2,000 level while peripheral DCB cuts are significantly shallower—"clinically essential + favorable competitive landscape" categories see relatively controllable cuts; ③ The fifth national batch allows moderate premiums for next-generation products, and the innovation green channel was previously exempt—HeartFlow's 11 green-channel products (including Hector multi-branch and Aorfix) may receive innovation-group protection. Conclusion: three elements in the bid-opening rules—"price cap + innovation exception + volume allocation ratio"—matter more for value than the bid-opening timing itself; any precise estimate before documents are published is conditional. Post-VBP-normalization valuation paradigm: the market assigns multiples by "VBP exposure ratio" rather than "current growth"—this is exactly the logic behind "each 5-percentage-point rise in overseas + peripheral share lifts the valuation center," and the valuation implication of the path 42.4% (2026H1 overseas + peripheral combined share) → 48–50% (2026E) → 50%+ (2027E).
(2) The registration pipeline is the product lifecycle. Class III certificates require 5–10 years of R&D plus 1–2 years of commercialization ramp (approval → hospital adoption → academic education → volume ramp; management acknowledges the long cycle), meaning device company growth is "pipeline-delivery based" rather than "capacity-release based." HeartFlow's pipeline: approved, pending volume ramp—Fishhawk mechanical thrombectomy catheter (scarce domestic category, benchmarked against Medtronic Indigo), TorqueFlex/HawkMaster/FinderSphere (approved 2026H1); under registration review—Aegis II abdominal aortic stent, HepaFlow TIPS stent graft (innovation pathway), SunRiver below-the-knee drug balloon (dual NMPA + CE MDR filings); clinical/designation stage—Hector multi-branch stent (multicenter trials + FDA Breakthrough Device designation; US approval timing per company "not yet predictable"). Product iteration is simultaneously a hedge against VBP (generational premiums from Castor → Cratos → Hector). Risks are symmetric: R&D spending fell 51.5% over two years before rebounding +26% in 2026H1; if approval timing slips (2 products were already delayed from 2025 commitments), the post-2028 growth center will be revised down.
Verdict: Cautiously bullish (12 months, confidence 0.58). The current price of RMB 84.90 trades at a ~23–30% discount to the base-case fair value of RMB 107–122 (safety margin ~26%), with probability-weighted expected return of ~+32%; but realization depends on two exogenous events (VBP rules, parent company resumption), and the company's own earnings momentum (2026H1 net to parent +2.45%) is not strong—hence no higher confidence is assigned. Strategically, the current price range offers value for staggered accumulation; above RMB 107 the stock enters fair-value territory and requires revaluation, and at RMB 120 (upper edge of base case) the safety margin is exhausted; below RMB 65 (upper edge of bear case) would imply the market is pricing a severe VBP scenario, warranting a full reassessment of the thesis rather than averaging down.
Key Risk Alerts (ranked by impact): ① Aortic VBP lands with a 40%+ cut and no exceptions (bear case RMB 54–65, net to parent -35% to -40%); ② MicroPort disposes of its HeartFlow stake or the trading halt becomes prolonged (event shock -15% to -25%); ③ Receivables/rebates deteriorate into impairments (channel destocking, single-quarter net profit -8% to -15%); ④ Peripheral "price-for-volume" fails and overseas growth falls below 15% (second curve falsified); ⑤ Goodwill impairment of RMB 465 mn (OMD/Lombard, safety margin ~10%); ⑥ Preferential 15% tax rate expires and is re-examined in 2027 (static net profit -11.8%).
Monitoring Points for the Next 12 Months: 2026-10-30 Q3 report (overseas nominal growth, peripheral turning positive, receivables/rebates/impairment line items); 2026Q4–2027Q2 Hebei-led aortic VBP documents and bid opening (price-cap rules, innovation exception clauses, number of alliance provinces); 2026Q4–2027Q1 MicroPort Medical resumption and group asset disposal developments; from 2026Q4, hospital adoption and ramp of Fishhawk and other new products; 2027H1 approval window for Aegis II/HepaFlow; 2027-03 annual report dividend plan and R&D spending ratio verification.
This report is based on the closing price as of 2026-10-09 (RMB 84.90) and previously public information. Data sources: HeartFlow Medical 2023–2025 annual reports, 2026 Q1/interim reports, investor relations minutes (2026-08-28, 2026-09-24), Hebei Provincial Healthcare Security Administration VBP notices, NHSA VBP batch announcements, Frost & Sullivan industry data (as cited in company annual reports), LeadLeo Research, CICC research reports (2026-08-30), and public news reports. Forward-looking estimates herein are analytical inferences and do not constitute investment advice.